Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

SIMPLE SUMMARY: Immunotherapies prolong survival of metastatic non-small-cell lung cancer patients. However, their efficacy in patients with very poor general condition is unknown. Best supportive care is the standard of care for these patients because chemotherapy is more toxic and less effective t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gounant, Valérie, Duruisseaux, Michael, Soussi, Ghassen, Van Hulst, Sylvie, Bylicki, Olivier, Cadranel, Jacques, Wislez, Marie, Trédaniel, Jean, Spano, Jean-Philippe, Helissey, Carole, Chouaid, Christos, Molinier, Olivier, Dhalluin, Xavier, Doucet, Ludovic, Hureaux, José, Cazes, Aurélie, Zalcman, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958129/
https://www.ncbi.nlm.nih.gov/pubmed/33801285
http://dx.doi.org/10.3390/cancers13051040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958129/
https://www.ncbi.nlm.nih.gov/pubmed/33801285
http://dx.doi.org/10.3390/cancers13051040

Ejemplares similares